中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 合肥物质科学研究院
  3. 中国科学院合肥物质科学研究院
Associations of Clinical and Molecular Characteristics with the Response to Immune Checkpoint Blockade in Advanced Gastric Cancers

文献类型：期刊论文

作者Xu, Xiaoqing7,8; Li, Jingjing7; Gao, Yiding6; Lv, Wangxia5; Wei, Qing7; Tang, Xiaowan4; Hu, Jinlin3; Yuan, Xing2; Wu, Wei3; Zhang, Lingnan1
刊名JOURNAL OF ONCOLOGY
出版日期2022-03-04
卷号2022
ISSN号1687-8450
DOI10.1155/2022/2162229
通讯作者Zhu, Xiu(zhuxiu2005@163.com) ; Xu, Qi(hzxuqi@sina.cn)
英文摘要Purpose. Immunotherapy provides a new treatment option for advanced gastric cancer (AGC). This study aims to explore the response markers of immunotherapy in AGCs. Methods. Next-generation sequencing was performed on 44 AGC patients who received immune checkpoint inhibitors and the associations between their outcomes after combination immunotherapy, and the clinicopathological/molecular characteristics were analyzed. Results. The current study cohort had a median progression-free survival (PFS) of 5.9 months, an overall survival (OS) of 12.1 months, and an objective response rate (ORR) of 36.4%. Through multivariable analysis of the clinical characteristics, primary tumor resection (HR = 2.66, 95% CI: 1.06-6.70, p=0.037) and increased proportion of lymphocytes after combination immunotherapy (HR = 0.40, 95% CI: 0.16-0.99, p=0.048) were revealed as independent predictors for patient outcomes. All the 18 patients who underwent genetic profiling were microsatellite-stable with a median TMB of four mutations per Mb. ATM alterations, PI3K pathway mutations, increased TMB, and positive PD-L1 expression were associated with the increased trend of PFS and ORR. According to the combination of baseline lymphocyte count, ATM mutation, TMB status, and PD-L1 expression, patients were stratified into higher- and lower-risk groups, with the lower-risk group showing improved PFS (HR = 4.7e-10, 95% CI: 0-inf, p=0.02) and ORR (75% vs. 0%, p=0.007). Conclusion. Several highly relevant potential biomarkers predictive of immunotherapy response in AGC patients have been identified in this research.
WOS关键词GASTROESOPHAGEAL JUNCTION ; PHASE-III ; 1ST-LINE THERAPY ; DOUBLE-BLIND ; OPEN-LABEL ; NIVOLUMAB ; 5-FLUOROURACIL/CISPLATIN ; CAPECITABINE/CISPLATIN ; CHEMOTHERAPY ; MULTICENTER
资助项目Program of Zhejiang Provincial TCM Sci-tech Plan[2021ZZ005] ; Medical Health Plan of Zhejiang Province[2022KY666]
WOS研究方向Oncology
语种英语
出版者HINDAWI LTD
WOS记录号WOS:000783427200002
资助机构Program of Zhejiang Provincial TCM Sci-tech Plan ; Medical Health Plan of Zhejiang Province
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/128559]  
专题中国科学院合肥物质科学研究院
通讯作者Zhu, Xiu; Xu, Qi
作者单位1.Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Radiol Dept,Inst Basic Med & Canc IBMC,Canc Hosp, Hangzhou, Zhejiang, Peoples R China
2.Hangzhou Hosp, Zhejiang Med & Hlth Grp, Dept Med Oncol, Hangzhou, Peoples R China
3.Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Pathol,Inst Basic Med & Canc IBMC,Canc Hosp, Hangzhou, Zhejiang, Peoples R China
4.Taizhou First Peoples Hosp, Dept Hematol Oncol, Taizhou, Peoples R China
5.Chinese Acad Sci, Univ Chinese Acad Sci, Inst Basic Med & Canc IBMC, Zhejiang Canc Hosp,Dept Colorectal Med Oncol,Canc, Hangzhou, Zhejiang, Peoples R China
6.Jiaxing Univ, Affiliated Hosp 2, Dept Oncol, Jiaxing, Peoples R China
7.Chinese Acad Sci, Dept Hepatopancreatobiliary & Gastr Med Oncol, Inst Basic Med & Canc IBMC, Zhejiang Canc Hosp,Univ Chinese Acad Sci,Canc, Hangzhou, Zhejiang, Peoples R China
8.Zhejiang Chinese Med Univ, Clin Med Coll 2, Dept Med Oncol, Hangzhou, Peoples R China
推荐引用方式
GB/T 7714		 Xu, Xiaoqing,Li, Jingjing,Gao, Yiding,et al. Associations of Clinical and Molecular Characteristics with the Response to Immune Checkpoint Blockade in Advanced Gastric Cancers[J]. JOURNAL OF ONCOLOGY,2022,2022.
APA Xu, Xiaoqing.,Li, Jingjing.,Gao, Yiding.,Lv, Wangxia.,Wei, Qing.,...&Xu, Qi.(2022).Associations of Clinical and Molecular Characteristics with the Response to Immune Checkpoint Blockade in Advanced Gastric Cancers.JOURNAL OF ONCOLOGY,2022.
MLA Xu, Xiaoqing,et al."Associations of Clinical and Molecular Characteristics with the Response to Immune Checkpoint Blockade in Advanced Gastric Cancers".JOURNAL OF ONCOLOGY 2022(2022).

入库方式： OAI收割

来源：合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。